Raloxifene (Ralo), a commonly used selective oestrogen‐receptor modulator to treat osteoporosis in postmenopausal women, was predicted to target PKN1 according to the bioinformatics team from the School of Mathematics, Tianjin Nankai University. This evidence concerns the gene PKN1 and osteoporosis.